NCT06478030 Combined Screening for Gastrointestinal Tumors
| NCT ID | NCT06478030 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Gastrointestinal Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 200,000 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200,000 participants in total. It began in 2023-03-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All participants are required to complete a questionnaire, a Helicobacter pylori (H. pylori) test, and a fecal immunochemical test (FIT). The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history. After quality control, the data is entered by staff into the Zhejiang Province Cancer Screening Information Platform. Risk assessments are performed based on the data collected and high-risk individuals are recommended for clinical screening. Additionally, tongue image, stool, urine, blood, tongue coating, saliva, gastric juice, and fresh tissue (gastric mucosa tissue and/or intestinal polyp tissue) samples are collected from all participants undergoing clinical screening. Participants are required to complete at least one passive follow-up annually. Active follow-ups are conducted for those with positive screening results to ensure timely completion of endoscopic examinations. For those who have not undergone endoscopic examinations despite positive screening results, health education is provided, and they are mobilized at least four times within one month to complete endoscopic examinations. For participants diagnosed and treated for precancerous lesions and tumors, diagnostic and treatment data must be collected, and they are encouraged to follow up as per medical advice. Both active and passive follow-up results must be recorded in the screening follow-up information record form and reported to the Zhejiang Province Cancer Screening Information Platform. This is a government collaboration project. All subjects will also be followed by record linkage to Cancer Register and Population Register.
Eligibility Criteria
Inclusion Criteria: * Subject residents from Zhejiang Province. * Subject is able to comprehend, sign, and date the written informed consent document to participate in the study. * Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study. Exclusion Criteria: * Subject has heavy cardiovascular, liver or kidney disease. * Subject is already suffering from malignant tumors of the digestive tract. * Subject has severe intellectual disabilities or language communication barriers. * Subject has had gastrointestinal endoscopy in the past year.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06478030 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 74 Years, studying Gastrointestinal Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06478030 currently recruiting?
Yes, NCT06478030 is actively recruiting participants. Contact the research team at chengxd@zjcc.org.cn for enrollment information.
Where is the NCT06478030 trial being conducted?
This trial is being conducted at Jinhua, China, Ningbo, China.
Who is sponsoring the NCT06478030 clinical trial?
NCT06478030 is sponsored by Zhejiang Cancer Hospital. The trial plans to enroll 200,000 participants.